{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endothelin+Receptor+Antagonists&page=2",
    "query": {
      "intervention": "Endothelin Receptor Antagonists",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Endothelin+Receptor+Antagonists&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T14:23:08.570Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05373108",
      "title": "Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiac Allograft Vasculopathy"
      ],
      "interventions": [
        {
          "name": "Macitentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2022-05-19",
      "completion_date": "2023-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-03-12",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05373108"
    },
    {
      "nct_id": "NCT01077297",
      "title": "Tezosentan in Pulmonary Arterial Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Tezosentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Idorsia Pharmaceuticals Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2010-08",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2018-07-09",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01077297"
    },
    {
      "nct_id": "NCT01884675",
      "title": "Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Ambrisentan 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 33,
      "start_date": "2013-09",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Dallas, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884675"
    },
    {
      "nct_id": "NCT03738150",
      "title": "A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SOC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2019-04-19",
      "completion_date": "2022-03-22",
      "has_results": true,
      "last_update_posted_date": "2024-08-27",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 4,
      "location_summary": "Tucson, Arizona • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03738150"
    },
    {
      "nct_id": "NCT02936687",
      "title": "Mechanisms of Cerebrovascular Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome X"
      ],
      "interventions": [
        {
          "name": "NOS Inhibition",
          "type": "DRUG"
        },
        {
          "name": "ET-1 Inhibition",
          "type": "DRUG"
        },
        {
          "name": "NOS Inhibition Placebo",
          "type": "DRUG"
        },
        {
          "name": "3 Tesla MRI",
          "type": "DEVICE"
        },
        {
          "name": "Intravenous Catheter",
          "type": "DEVICE"
        },
        {
          "name": "Oral Glucose Tolerance Test",
          "type": "OTHER"
        },
        {
          "name": "ET-1 Inhibition Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 59,
      "start_date": "2017-01-31",
      "completion_date": "2021-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02936687"
    },
    {
      "nct_id": "NCT00593905",
      "title": "Pharmacogenomics in Pulmonary Arterial Hypertension",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Arterial Hypertension",
        "Pulmonary Hypertension",
        "PAH WHO Group I"
      ],
      "interventions": [
        {
          "name": "Sitaxsentan",
          "type": "DRUG"
        },
        {
          "name": "Bosentan, Ambrisentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Penn Allegheny Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "2005-07",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2021-12-09",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593905"
    },
    {
      "nct_id": "NCT01794078",
      "title": "A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Mountain Sickness and Fatigue"
      ],
      "interventions": [
        {
          "name": "Aminophylline 400 mg",
          "type": "DRUG"
        },
        {
          "name": "Ambrisentan 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Robert J Noveck, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 92,
      "start_date": "2013-09",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-11-13",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01794078"
    },
    {
      "nct_id": "NCT06925750",
      "title": "A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Background PAH Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2025-05-12",
      "completion_date": "2028-06-16",
      "has_results": false,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06925750"
    },
    {
      "nct_id": "NCT04576988",
      "title": "A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Sotatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background PAH Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2021-01-25",
      "completion_date": "2022-12-06",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04576988"
    },
    {
      "nct_id": "NCT00452283",
      "title": "Changes in Eye Pressure and Anterior Chamber Depth With Oral Endothelin Antagonist Therapy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glaucoma",
        "Pulmonary Hypertension"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 23,
      "start_date": "2007-03",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-09-29T14:23:08.570Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00452283"
    }
  ]
}